• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Prevalence of Cutaneous Squamous Cell Carcinoma (CSCC) & Basal Cell Carcinoma (BCC)


Panelists discuss the current prevalence and treatment landscape of cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC).

This is a video synopsis/summary of a Peer Exchange involving Jason Luke, MD, FACP; Christopher Barker, MD; Omid Hamid, MD; Vishal Patel, MD; and Catherine Pisano, MD.

Patel provided an overview of cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC), the 2 most common types of nonmelanoma skin cancer. He explained that cSCC and BCC arise from keratinocytes in the epidermis and can present as rough, scaly patches or nodules that continue to grow and won’t heal. Pisano highlighted that cSCC and especially BCC are extremely common, with incidence rising as the population ages. She noted that cSCCis responsible for more cancer deaths annually than melanoma or Merkel cell carcinoma. Hamid then discussed immunotherapy with PD-1 inhibitors as a new standard of care for advanced cSCC and BCC. Hamid concluded that immunotherapy not only drives responses in advanced keratinocyte carcinomas but exhibits durability that could form the backbone of future combination regimens.

Video synopsis is AI-generated and reviewed by AJMC editorial staff. 

Related Videos
Video 2 - "Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer"
ateyeh soroush
dr kathy zackowski
dr mitzi joi williams
dr krystyn van vliet
Related Content
© 2024 MJH Life Sciences
All rights reserved.